Table of Contents
Leukemia Research and Treatment
Volume 2015 (2015), Article ID 982395, 12 pages
http://dx.doi.org/10.1155/2015/982395
Research Article

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

1Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT-University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, 6060 Hall in Tirol, Austria
2Area Health Technology Assessment, ONCOTYROL-Center for Personalized Cancer Medicine, Karl-Kapferer-Straße 5, 6020 Innsbruck, Austria
3Department of Pharmacotherapy, University of Utah, 30 South 2000, Salt Lake City, UT 84112, USA
4Huntsman Cancer Institute, University of Utah Hospitals & Clinics, 2000 Circle of Hope, Salt Lake City, UT 84112, USA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98104, USA
6Program in Personalized Health, University of Utah, 15 North 2030 East, Room 2110, Salt Lake City, UT 84112, USA
7Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, 718 Huntington Avenue, Boston, MA 02215, USA
8Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac Street, Boston, MA 02114, USA

Received 25 August 2015; Revised 5 November 2015; Accepted 11 November 2015

Academic Editor: Mario Tiribelli

Copyright © 2015 Ursula Rochau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Ghatnekar, F. Hjalte, and M. Taylor, “Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib—a Swedish model application,” Acta Oncologica, vol. 49, no. 6, pp. 851–858, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Pavey, M. Hoyle, O. Ciani et al., “Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses,” Health Technology Assessment, vol. 16, no. 42, pp. 1–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Baccarani, S. Pileri, J.-L. Steegmann, M. Muller, S. Soverini, and M. Dreyling, “Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, Article ID mds228, pp. vii72–vii77, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. X. An, A. K. Tiwari, Y. Sun, P.-R. Ding, C. R. Ashby Jr., and Z.-S. Chen, “BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review,” Leukemia Research, vol. 34, no. 10, pp. 1255–1268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. C. Trask, D. Cella, N. Besson, V. Kelly, T. Masszi, and D.-W. Kim, “Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia,” Leukemia Research, vol. 36, no. 4, pp. 438–442, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Experts in Chronic Myeloid Leukemia, “The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts,” Blood, vol. 121, no. 22, pp. 4439–4442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. D. U. Himmelstein, D. Thorne, and S. Woolhandler, “Medical bankruptcy in Massachusetts: has health reform made a difference?” The American Journal of Medicine, vol. 124, no. 3, pp. 224–228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Siebert, “When should decision-analytic modeling be used in the economic evaluation of health care,” The European Journal of Health Economics, vol. 4, no. 3, pp. 143–150, 2003. View at Google Scholar
  10. L. B. Russell, M. R. Gold, J. E. Siegel, N. Daniels, and M. C. Weinstein, “The role of cost-effectiveness analysis in health and medicine,” The Journal of the American Medical Association, vol. 276, no. 14, pp. 1172–1177, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Rochau, G. Sroczynski, D. Wolf et al., “Medical decision analysis for first-line therapy of chronic myeloid leukemia,” Leukemia and Lymphoma, vol. 55, no. 8, pp. 1758–1767, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2014, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm.
  13. J. E. Cortes, D.-W. Kim, H. M. Kantarjian et al., “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3486–3492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Hehlmann, H. Heimpel, J. Hasford et al., “Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group,” Blood, vol. 84, no. 12, pp. 4064–4077, 1994. View at Google Scholar
  15. R. Hehlmann, U. Berger, M. Pfirrmann et al., “Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea,” Leukemia, vol. 17, no. 8, pp. 1529–1537, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Gambacorti-Passerini, J. Cortes, D. W. Kim et al., “Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up,” Journal of Clinical Oncology, vol. 29, supplement, abstract 6509, 2011. View at Google Scholar
  17. J. Cortes, A. Maru, C. De Souza et al., “Bosutinib versus imatinib in newly diagnosed chronic phase phronic myeloid leukemia—BELA trial: 24-month follow-up,” Blood, vol. 118, abstract 455, 2011, ASH Annual Meeting Abstracts. View at Google Scholar
  18. C. Gambacorti-Passerini, J. H. Lipton, G. Y. Tee et al., “BELA trial update: bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up,” Journal of Clinical Oncology, vol. 30, abstract 6512, 2012. View at Google Scholar
  19. H. Kantarjian, N. P. Shah, A. Hochhaus et al., “Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2260–2270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. N. P. Shah, H. A. Kantarjian, A. Hochhaus et al., “Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid 18 leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up,” Blood, vol. 116, abstract 206, 2010, (ASH Annual Meeting Abstracts). View at Google Scholar
  21. H. M. Kantarjian, N. P. Shah, J. E. Cortes et al., “Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION),” Blood, vol. 119, no. 5, pp. 1123–1129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Saglio, D.-W. Kim, S. Issaragrisil et al., “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2251–2259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. M. Kantarjian, A. Hochhaus, G. Saglio et al., “Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial,” The Lancet Oncology, vol. 12, no. 9, pp. 841–851, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. R. A. Larson, A. Hochhaus, T. P. Hughes et al., “Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. ENESTnd 3-year follow-up,” Leukemia, vol. 26, no. 10, pp. 2197–2203, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. J. E. Cortes, H. M. Kantarjian, T. H. Brummendorf et al., “Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib,” Blood, vol. 118, no. 17, pp. 4567–4576, 2011. View at Google Scholar
  26. C. Gambacorti-Passerini, D. W. Kim, A. G. Turkina et al., “Bosutinib (SKI-606) as second-line therapy for chronic phase chronic myeloid leukemia (CP CML) following imatinib failure: analyses of cross-intolerance and response by prior response to imatinib,” Journal of European Hematology Association, vol. 96, no. 2, abstract 0146, 2011. View at Google Scholar
  27. N. P. Shah, H. M. Kantarjian, D.-W. Kim et al., “Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3204–3212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. N. P. Shah, D.-W. Kim, H. Kantarjian et al., “Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib,” Haematologica, vol. 95, no. 2, pp. 232–240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. N. P. Shah, J. E. Cortes, C. A. Schiffer et al., “Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib,” Journal of Clinical Oncology, vol. 29, supplement, abstract 6512, 2011. View at Google Scholar
  30. H. M. Kantarjian, F. Giles, N. Gattermann et al., “Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance,” Blood, vol. 110, no. 10, pp. 3540–3546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. M. Kantarjian, F. Giles, K. N. Bhalla et al., “Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study,” Blood (ASH Annual Meeting Abstracts), vol. 112, abstract 3238, 2008. View at Google Scholar
  32. H. M. Kantarjian, F. J. Giles, K. N. Bhalla et al., “Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results,” Blood, vol. 117, no. 4, pp. 1141–1145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. F. J. Giles, P. D. le Coutre, J. Pinilla-Ibarz et al., “Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study,” Leukemia, vol. 27, no. 1, pp. 107–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. D. W. Kim, J. Cortes, J. Pinilla-Ibarz et al., “Efficacy and safety of ponatinib according to prior approved Tyrosine Kinase Inhibitor (TKI) therapy in patients with chronic myeloid leukemia in chronic phase (CP-CML): results from the pace trial,” Blood, vol. 120, abstract 3749, 2012, ASH Annual Meeting Abstracts. View at Google Scholar
  35. J. Cortes, D. W. Kim, J. Pinilla-Ibarz et al., “A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial,” Blood, vol. 120, abstract 163, 2012, ASH Annual Meeting Abstracts. View at Google Scholar
  36. J. Cortes, D. W. Kim, J. Pinilla-Ibarz et al., “A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR ABL mutation: 12 month follow up of the PACE trial,” in Proceedings of the 54th ASH Annual Meeting and Exposition, abstract 163, Atlanta, Ga, USA, 2012.
  37. J. E. Cortes, D.-W. Kim, J. Pinilla-Ibarz et al., “A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias,” The New England Journal of Medicine, vol. 369, no. 19, pp. 1783–1796, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Kantarjian, S. O'Brien, M. Talpaz et al., “Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure,” Cancer, vol. 109, no. 8, pp. 1556–1560, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Cervantes, A. López-Guillermo, F. Bosch, M.-J. Terol, C. Rozman, and E. Montserrat, “An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia,” European Journal of Haematology, vol. 57, no. 4, pp. 286–291, 1996. View at Google Scholar · View at Scopus
  40. S. D. Reed, K. J. Anstrom, J. A. Ludmer, G. A. Glendenning, and K. A. Schulman, “Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia,” Cancer, vol. 101, no. 11, pp. 2574–2583, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Dalziel, A. Round, R. Garside, and K. Stein, “Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia,” Pharmacoeconomics, vol. 23, no. 5, pp. 515–526, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. D. G. Fryback, E. J. Dasbach, R. Klein et al., “The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors,” Medical Decision Making, vol. 13, no. 2, pp. 89–102, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. S. J. Lee, K. M. Kuntz, M. M. Horowitz et al., “Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis,” Annals of Internal Medicine, vol. 127, no. 12, pp. 1080–1088, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. Thomas Reuters Micromedec Clinical Evidence Solutions, Red Book, 2014, http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red_book/.
  45. S. D. Reed, K. J. Anstrom, Y. Li, and K. A. Schulman, “Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia,” PharmacoEconomics, vol. 26, no. 5, pp. 435–446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. A. M. Saito, C. Cutler, D. Zahrieh et al., “Costs of allogeneic hematopoietic cell transplantation with high-dose regimens,” Biology of Blood and Marrow Transplantation, vol. 14, no. 2, pp. 197–207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. HCUPnet, “Healthcare Cost and Utilization Project,” Agency for Healthcare Research and Quality, Rockville, Md, USA, http://hcupnet.ahrq.gov/.
  48. U. Rochau, G. Sroczynski, D. Wolf et al., “Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia,” Leukemia & Lymphoma, vol. 56, no. 8, pp. 2315–2325, 2015. View at Publisher · View at Google Scholar
  49. J. J. Caro, A. H. Briggs, U. Siebert, and K. M. Kuntz, “Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1,” Medical Decision Making, vol. 32, no. 5, pp. 667–677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Roberts, L. B. Russell, A. D. Paltiel, M. Chambers, P. McEwan, and M. Krahn, “Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2,” Medical Decision Making, vol. 32, no. 5, pp. 678–689, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. U. Siebert, O. Alagoz, A. M. Bayoumi et al., “State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3,” Medical Decision Making, vol. 32, no. 5, pp. 690–700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. H. Briggs, M. C. Weinstein, E. A. L. Fenwick, J. Karnon, M. J. Sculpher, and A. D. Paltiel, “Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6,” Medical Decision Making, vol. 32, no. 5, pp. 722–732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. D. M. Eddy, W. Hollingworth, J. J. Caro, J. Tsevat, K. M. McDonald, and J. B. Wong, “Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7,” Medical Decision Making, vol. 32, no. 5, pp. 733–743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. M. R. Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein, Cost-Effectiveness in Health and Medicine, Oxford University Press, New York, NY, USA, 1996.
  55. American Cancer Society, “What are the key statistics about chronic myeloid leukemia?” 2012, http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-key-statistics.
  56. D. D. Stenehjem, F. Albright, K.-L. Kuo et al., “Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database,” Journal of the National Comprehensive Cancer Network, vol. 12, no. 8, pp. 1113–1121, 2014. View at Google Scholar · View at Scopus
  57. E. Arias, “National Center for Health Statistics. United States life tables, 2008,” National Vital Statistics Reports, vol. 61, no. 3, pp. 1–64, 2012. View at Google Scholar
  58. U. Rochau, M. Kluibenschaedl, D. Stenehjem et al., “The United States physican survey to populate a decision-analytic model for the treatment of chronic myeloid leukemia,” Value in Health, vol. 16, no. 7, p. A423, 2013, ISPOR 16th Annual European Congress, November 2–6 Dublin Ireland. View at Publisher · View at Google Scholar
  59. M. Hunink, P. Glasziou, J. Siegel et al., Decision Making in Health and Medicine. Integrating Evidence and Values, Cambridge University Press, Cambridge, UK, 2001.
  60. The EuroQol Group, “EuroQol—a new facility for the measurement of health-related quality of life,” Health Policy, vol. 16, no. 3, pp. 199–208, 1990. View at Publisher · View at Google Scholar
  61. US. Bureau of Labor Statistics, “Consumer Price Index for All Urban Consumers: Medical care services,” Retrieved from FRED, Federal Reserve Bank of St. Louis, 2014, http://research.stlouisfed.org/fred2/series/CUSR0000SAM2.
  62. US Bureau of Labor Statistics, Consumer Price Index for All Urban Consumers: Medical Care Commodities, FRED, Federal Reserve Bank of St. Louis, 2014, http://research.stlouisfed.org/fred2/series/CUSR0000SAM1.
  63. M. W. Kattan, Encyclopedia of Medical Decision Making, Sage, Thousand Oaks, Calif, USA, 2009.
  64. The Congress of the United States Congressional Budget Office, How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry, 1998, http://www.cbo.gov/.
  65. National Comprehensive Cancer Network (NCCN), “NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic myelogeneous leukemia,” December 2013, http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf.
  66. R. M. Conti, W. V. Padula, and R. A. Larson, “Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU,” Annals of Hematology, vol. 94, supplement 2, pp. 249–257, 2015. View at Publisher · View at Google Scholar
  67. National Institute for Health and Care Excellence, Process and Methods Guides. Guide to the Methods of Technology Appraisal, NICE, 2013, https://www.nice.org.uk/article/pmg9/chapter/foreword.
  68. Raad voor de Volksgezondheid en Zorg aan de minister van Volksgezondheid, Zinnige en duurzame zorg, pp. 1–112, December 2013, http://www.rvz.net/uploads/docs/Advies_-_Zinnige_en_duurzame_zorg.pdf.
  69. P. J. Neumann, E. A. Sandberg, C. M. Bell, P. W. Stone, and R. H. Chapman, “Are pharmaceuticals cost-effective? A review of the evidence,” Health Affairs, vol. 19, no. 2, pp. 92–109, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. World Health Organization, “Cost-effectiveness thresholds,” 2005, http://www.who.int/choice/costs/CER_levels/en/.
  71. P. A. Ubel, R. A. Hirth, M. E. Chernew, and A. M. Fendrick, “What is the price of life and why doesn't it increase at the rate of inflation?” Archives of Internal Medicine, vol. 163, no. 14, pp. 1637–1641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. Rate Inflation, Historical Consumer Price Index (CPI) for United States of America (1982 to 2014), 2015, http://www.rateinflation.com/consumer-price-index/usa-historical-cpi?start-year=1982&end-year=2014.
  73. R. S. Braithwaite, D. O. Meltzer, J. T. King Jr., D. Leslie, and M. S. Roberts, “What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?” Medical Care, vol. 46, no. 4, pp. 349–356, 2008. View at Publisher · View at Google Scholar
  74. J. L. Anderson, P. A. Heidenreich, P. G. Barnett et al., “ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 63, no. 21, pp. 2304–2322, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. P. B. Bach, “Limits on medicare's ability to control rising spending on cancer drugs,” The New England Journal of Medicine, vol. 360, no. 6, pp. 626–633, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. NHS England, “The Cancer Drugs Fund,” January 2015, http://www.england.nhs.uk/ourwork/pe/cdf/.
  77. M. Hoyle, G. Rogers, T. Moxham, Z. Liu, and K. Stein, “Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia,” Value in Health, vol. 14, no. 8, pp. 1057–1067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Loveman, K. Cooper, J. Bryant, J. L. Colquitt, G. K. Frampton, and A. Clegg, “Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation,” Health Technology Assessment, vol. 16, no. 23, pp. 1–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Rogers, M. Hoyle, J. Thompson Coon et al., “Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation,” Health Technology Assessment, vol. 16, no. 22, pp. 1–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. S. J. Whitehead and S. Ali, “Health outcomes in economic evaluation: the QALY and utilities,” British Medical Bulletin, vol. 96, no. 1, pp. 5–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. S. O'Brien, E. Berman, J. O. Moore et al., “NCCN task force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia,” Journal of the National Comprehensive Cancer Network, vol. 9, supplement 2, pp. S1–S25, 2011. View at Google Scholar · View at Scopus
  82. P. Valent, E. Hadzijusufovic, G.-H. Schernthaner, D. Wolf, D. Rea, and P. Le Coutre, “Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors,” Blood, vol. 125, no. 6, pp. 901–906, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. F.-X. Mahon, D. Réa, J. Guilhot et al., “Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial,” The Lancet Oncology, vol. 11, no. 11, pp. 1029–1035, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. D. M. Ross, S. Branford, J. F. Seymour et al., “Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study,” Blood, vol. 122, no. 4, pp. 515–522, 2013. View at Publisher · View at Google Scholar · View at Scopus